Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Scinai Immunotherapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, risk, earnings, valuation, dividends and profitability.
Volatility & Risk
Scinai Immunotherapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics’ rivals have a beta of -1.85, suggesting that their average share price is 285% less volatile than the S&P 500.
Insider & Institutional Ownership
58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Scinai Immunotherapeutics and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Scinai Immunotherapeutics | $1.31 million | -$8.31 million | 0.18 |
| Scinai Immunotherapeutics Competitors | $718.90 million | $8.79 million | -18.37 |
Scinai Immunotherapeutics’ rivals have higher revenue and earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of recent recommendations for Scinai Immunotherapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scinai Immunotherapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Scinai Immunotherapeutics Competitors | 9926 | 15341 | 45751 | 1601 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 110.72%. Given Scinai Immunotherapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Scinai Immunotherapeutics has less favorable growth aspects than its rivals.
Profitability
This table compares Scinai Immunotherapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scinai Immunotherapeutics | N/A | N/A | N/A |
| Scinai Immunotherapeutics Competitors | -12,516.26% | -215.37% | -31.41% |
About Scinai Immunotherapeutics
Scinai Immunotherapeutics is an Israel-based biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. Its research centers on antibody-based treatments, including compact antibody formats known as nanobodies. The company also provides research, development and manufacturing services to biotechnology and pharmaceutical companies through its Scinai BioServices business. These services support the development of biologic drugs and other products. Scinai was formerly known as BiondVax Pharmaceuticals, which worked on a universal influenza vaccine before the company shifted its focus to immunotherapies and biopharmaceutical services.
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
